MRI and clinical activity in MS patients after terminating treatment with interferon beta-1b

Multiple Sclerosis

Volumn 6, Issue 2, 2000, Pages 86-90

  Richert, Nancy D ^a,b   Zierak, Mary Christina ^a   Bash, Craig N ^a,c   Lewis, Bobbi K ^a   McFarland, Henry F ^a   Frank, Joseph A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Interferon beta 1b; Magnetic resonance imaging; Multiple sclerosis

Indexed keywords

INTERFERON BETA SERINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ACTIVITY; DRUG WITHDRAWAL; HUMAN; LONGITUDINAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; REFRACTORY PERIOD;

EID: 0033994836     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/135245800678827617     Document Type: Article

References (27)

1. Jacobs LD, et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39: 285-292.
2. Paty DW, Li DK. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 43: 662-667.
3. Stone LA, et al. (1995) The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 37: 611-619.
4. Kurtzke JF. (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444-1452.
5. DeCarli C, et al. (1992) Method for quantification of brain, ventricular, and subarachnoid CSF volumes from MR images. J Comput Assist Tomogr 16: 274-284.
6. Stone LA, et al. (1995) Changes in the amount of diseased white matter over time in patients with relapsing-remitting multiple sclerosis. Neurology 45: 1808-1814.
7. Silver NC, et al. (1997) Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging. Brain 120: 1149-1161.
8. Filippi M et al. (1996) Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS. Neurology 46: 379-384.
9. van der Meide PH, et al. (1998) Discontinuation of treatment with IFN-beta leads to exacerbation of experimental autoimmune encephalomyelitis in Lewis rats. Rapid reversal of the antiproliferative activity of IFN-beta and excessive expansion of autoreactive T cells as disease promoting mechanisms. J Neuroimmunol 84: 14-23.
10. Durelli L, et al. (1996) Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: disease activity resumes after stopping treatment. Neurology 47: 123-129.
11. Myhr KM, et al. (1999) Interferon-alpha2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian Study Group on Interferon-alpha in Multiple Sclerosis. Neurology 52: 1049-1056.
12. Arnason BG. (1996) Interferon beta in multiple sclerosis. Clin Immunol Immunopathol 81: 1-11.
13. Yong VW, Chabot S, Stuve O, Williams G. (1998) Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 51: 682-689.
14. Weinstock-Guttman B, Ransohoff RM, Kinkel RP, Rudick RA. (1995) The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol 37: 7-15.
15. Khan OA, et al. (1996) Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration. Neurology 46: 1639-1643.
16. Salmon P, et al. (1996) Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. J Interferon Cytokine Res 16: 759-764.
17. Rudick RA, et al. (1993) In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta. Neurology 43: 2080-2087.
18. Noronha A, Toscas A, Jensen MA. (1993) Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol 46: 145-153.
19. Kozovska ME, et al. (1999) Interferon beta induces T-helper 2 immune deviation in MS. Neurology 53: 1692-1697.
20. Kaser A, Deisenhammer F, Berger T, Tilg H. (1999) Interferon-beta 1b augments activation-induced T-cell death in multiple sclerosis patients [letter]. Lancet 353: 1413-1414.
21. Rudick RA, et al. (1998) In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology 50: 1294-1300.
22. Defazio G, et al. (1998) ICAM 1 expression and fluid phase endocytosis of cultured brain microvascular endothelial cells following exposure to interferon beta-1a and TNFalpha. J Neuroimmunol 88: 13-20.
23. Trojano M, et al. (1998) Serum soluble intercellular adhesion molecule-I in MS: relation to clinical and Gd-MRI activity and to rIFN beta-Ib treatment. Mult Scler 4: 183-187.
24. Calabresi PA, et al. (1997) Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b. Ann Neurol 41: 669-674.
25. Leppert D, et al. (1996) Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 40: 846-852.
26. Stuve O, et al. (1996) Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 40: 853-863.
27. Trojano M, et al. (1999) Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology 53: 1402-1408.